Samsung Biologics Inks Manufacturing Deal with GSK
SEOUL, May 22 (Korea Bizwire) — South Korea’s top pharmaceutical firm, Samsung Biologics Co., said Friday it has signed a tieup deal with multinational drug maker GlaxoSmithKline Plc. (GSK) to manufacture a GSK biosimilar product. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will commercially produce CSK’s lupus treatment, Benlysta, starting in 2022. The [...]